XENE · NASDAQ
Xenon Pharmaceuticals (XENE) Stock Price & Fundamentals
Xenon Pharmaceuticals (XENE) closed at $429.17 on Oct 9, 2026, up 1.31% from the previous close of $423.62.
Share price, past year
1Y +5.89%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $429.17 |
| Sep 30, 2026 | $424.94 |
| Aug 31, 2026 | $422.72 |
| Jul 31, 2026 | $412.45 |
| Jun 30, 2026 | $414.16 |
| May 29, 2026 | $428.77 |
| Apr 30, 2026 | $417.61 |
| Mar 31, 2026 | $392.06 |
| Feb 27, 2026 | $377.05 |
| Jan 30, 2026 | $384.95 |
| Dec 31, 2025 | $366.66 |
| Nov 28, 2025 | $408.55 |
| Oct 31, 2025 | $406.89 |
Key statistics
- Market cap
- $41.52B
- P/E (TTM)
- —
- EPS (TTM)
- −$4.74
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$409.20M
- Shares outstanding
- 96.8M
- Dividend yield
- —
- 52-week range
- $364.05 – $433.21
Xenon Pharmaceuticals's market cap is $41.52B, based on a share price of $429.17 and 96.8M shares outstanding as of Jun 30, 2026.
Financials
Xenon Pharmaceuticals reported revenue of $7.50M for fiscal 2025.
Xenon Pharmaceuticals reported a net loss of $345.91M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $7.50M | — | −$345.91M | −4,612.1% | −$4.36 | −$279.92M |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$234.33M | — | −$3.01 | −$184.46M |
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$182.39M | — | −$2.73 | −$156.73M |
| FY2022ended Dec 31, 2022 | $9.43M | −48.8% | −$125.37M | −1,329.0% | −$2.06 | −$103.92M |
| FY2021ended Dec 31, 2021 | $18.44M | −42.7% | −$78.88M | −427.9% | −$1.77 | −$71.55M |
| FY2020ended Dec 31, 2020 | $32.17M | +371.0% | −$28.84M | −89.7% | −$0.81 | −$50.76M |
| FY2019ended Dec 31, 2019 | $6.83M | +2,095.8% | −$41.60M | −609.1% | −$1.54 | −$5.95M |
| FY2017ended Dec 31, 2017 | $311.00K | −82.8% | −$30.70M | −9,872.7% | −$1.72 | −$29.04M |
| FY2016ended Dec 31, 2016 | $1.80M | −88.4% | −$23.00M | −1,275.5% | −$1.48 | — |
| FY2015ended Dec 31, 2015 | $15.58M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$110.74M | −$1.11 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$102.30M | −$1.17 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$105.26M | −$1.31 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$90.90M | −$1.15 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$84.71M | −$1.07 |
| Q1 FY2025ended Mar 31, 2025 | $7.50M | −$65.05M | −$0.83 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$65.69M | −$0.83 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$62.79M | −$0.81 |
Company profile
- Name
- Xenon Pharmaceuticals Inc.
- Ticker
- XENE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 200 - 3650 Gilmore Way, Burnaby
- Incorporated in
- A1
- Fiscal year ends
- December
- SEC CIK
- 0001582313
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 3, 2026
- May 7, 2026
- May 7, 2026
- Apr 13, 2026
- Mar 13, 2026
- Mar 12, 2026
Frequently asked questions
What is Xenon Pharmaceuticals's stock price?
Xenon Pharmaceuticals (XENE) closed at $429.17 on Oct 9, 2026, up 1.31% from the previous close of $423.62.
What is Xenon Pharmaceuticals's market cap?
Xenon Pharmaceuticals's market cap is $41.52B, based on a share price of $429.17 and 96.8M shares outstanding as of Jun 30, 2026.
How much revenue does Xenon Pharmaceuticals make?
Xenon Pharmaceuticals reported revenue of $7.50M for fiscal 2025.
Does Xenon Pharmaceuticals pay a dividend?
Xenon Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Xenon Pharmaceuticals Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures